Synvisc® in knee osteoarthritis

Future Rheumatology

Volumn 3, Issue 3, 2008, Pages 215-222

  Stitik, Todd P ^a   Kazi, Asad ^a   Kim, Jong Hyun ^a  

^a University Rehabilitation Associates   (United States)

Author keywords

Hyaluronan; Hyaluronic acid; Hylan GF 20; Osteoarthritis; Sodium hyaluronate; Synvisc ; Viscosupplementation

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CAPSAICIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; EUFLEXXA; HYALURONIC ACID; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; STEROID; SYNVISC ONE; TRAMADOL;

ANALGESIA; ARTICLE; CHEMICAL COMPOSITION; CHILL; CLINICAL TRIAL; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EXERCISE; FACE SWELLING; FLUSHING; HUMAN; INFLAMMATION; INJECTION SITE PAIN; KNEE OSTEOARTHRITIS; KNEE PAIN; MALAISE; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; PARESTHESIA; PATIENT SELECTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SUPPLEMENTATION; SWELLING; THROMBOCYTOPENIA; TOTAL KNEE REPLACEMENT; UNSPECIFIED SIDE EFFECT; URTICARIA;

EID: 47249100652     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.3.3.215     Document Type: Article

References (54)

1. Caborn D, Rush J, Lanzer W, Parenti D, Murray C; Synvisc 901 Study Group: A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J. Rheumatol. 31 (2), 333-343 (1994).
2. Buckwalter J, Saltzman C, Brown T: The impact of osteoarthritis: implications for research. Clin. Orthop. 427(Suppl.), S6-S15 (2004).
3. Felson DT, Zhang Y, Hannan MT et al.: The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 38, 1500-1505 (1995).
4. Stitik TP, Levy JA: Viscosupplementation (biosupplementation) for osteoarthritis. Am. J. Phys. Med. Rehabil. 85(Suppl.), S32-S50 (2006).
5. Jackson DW, Simon TM: Intra-articular distribution and residence time of Hylan A and B: a study in the goat kpee. Osteoarthr. Cartil. 14, 1248-1257 (2006).
6. Weiss C, Band P: Musculoskeletal applications of hyaluronan and hylan: potential uses in the foot and ankle. Implant. Biomat. 12, 497-517 (1995).
7. Synvisc® package insert. Genzyme Biosurgery, NJ, USA (2003).
8. Ettinger WH, Burns R, Messier SP et al.: A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis: the Fitness, Arthritis and Seniors Trial (FAST). JAMA 277, 25-31 (1997).
9. Waddell DD, Bricker DC: Total knee replacement delayed with Hylan G-F 20 use in patients with grade IV osteoarthritis. J. Manag. Care Pham. 13(2), 113-121 (2007).
10. Wobig M, Dickut A, Maier R, Vetter G: Viscosupplementation with hylan GF-20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin. Therapeut. 20, 410-423 (1998).
11. Fraser JRE, Kimton WG, Pierscioner BK et al.: The kinetics of hyaluronan in normal and acutely inflamed synovial joints: exploratory observations with experimental arthritis in sheep. Semin. Arthritis Rheum. 22(Suppl. 1), 9-17 (1993).
12. Namicki O, Toyoshima H, Morisaki N: Therapeutic effect of intra-articular injection of high molecular weight hyaluronic acid on osteoarthritis of the knee. Int. J. Clin. Pharmacol. Ther. Toxicol. 20, 501-507 (1982).
13. Brandt KD, Smith GN, Simon LS: Intraarticular injection of hyaluronan as treatment for knee osteoarthritis. Arthritis Rheum. 43, 1192-1203 (2000).
14. Genzyme Biosurgery: Synvisc® (Hylan GF-20) Dossier Based on the AMCP Format for Formulary Submissions Version 2.1: A Format for Submission of Clinical Economic Data in Support for Formulary Consideration by Health Care Systems in the United States. Genzyme Biosurgery, NJ, USA, 14, 15, 79-85, 87, 88 (2007).
15. Scale D, Wobig M, Wolpert W: Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr. Ther. Res. 55(3), 220-232 (1994).
16. Adams ME, Atkinson MH, Lussier AJ et al.: The role of viscosupplementation with hylan G-F 20 in the treatment of osteoarthritis of the knee. Osteoarthr. Cartil. 3, 213-226 (1995).
17. Dickson DJ, Hosie G, English JR: A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. J. Clin. Res. 4, 41-52 (2001).
18. Raynauld JP, Torrance GW, Band PA et al.: Canadian Knee OA Study Group: A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthr. Cartil. 10(7), 506-517 (2002).
19. Bellamy N, Campbell 1, Robinson V, Gee T, Bourne R, Wells G: Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst. Rev. 2(4), CD005328 (2006).
20. Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K, Müllner M: Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 172(8), 1039-1043 (2005).
21. Lo GH, LaValley M, McAlindon T, Felson DT: Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 290(23), 3115-3121 (2003).
22. Modawal A, Ferrer M, Choi HK, Castle JA: Hyaluronic acid injections relieve knee pain. J. Fam. Pract. 54(9), 758-767 (2005).
23. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM: Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J. Bone Joint Surg. Am. 86-A(3), 538-545 (2004).
24. Kirchner M, Marshall D: A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthr. Cartil. 14, 154-162 (2006).
25. Karlsson J, Sjögren LS, Lohmander LS: Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford) 41(11), 1240-1248 (2002).
26. Schiavinato A, Finesso M, Abatangelo G: Comparison of the effects of intra-articular injections of hyaluronan and its chemically cross-linked derivative (hylan G-F 20) in normal rabbit knee joints. Clin. Exp. Rheumatol. 19, 265-270 (2001).
27. Raman R, Dutta A, Day N, Shaw C, Johnson G: The efficacy of hylan GF-20 and sodium hyaluronate in the treatment of osteoarthritis of the knee - a prospective randomized double blinded clinical trial [abstract]. Osteoarthr. Cartil. 14(Suppl. B), S162 (2006).
28. Waddell DD, Cefalu CA, Bricker DC: A second course of hylan G-F 20 for the treatment of osteoarthritic knee pain: 12-month patient follow-up. J. Knee Surg. 18(1), 7-15 (2005).
29. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, de Médicis R: Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J. Rheumatol. 23, 1579-1585 (1996).
30. Raynauld JP, Goldsmith CH, Bellamy N et al.: Effectiveness and safety of repeat courses of hylan GF-20 in patients with knee osteoarthritis. Osteoarthr. Cartil. 13(2), 111-119 (2005).
31. Waddell DD, Bricker DC: Hylan GF-20 tolerability with repeat treatment in a large orthopedic practice: a retrospective review. J. Surg. Orthop. Adv. 15(1), 52-59 (2006).
32. Scali JJ: Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: a long term study. Eur. J. Rheumatol. Inflamm. 15, 57-62 (1995).
33. Marshal KW: Hylan GF-20 (Synvisc®) salvage of patients failing a standardized arthroscopic debridement treatment algorithm [poster]. Presented at: The European Federation of National Association of Orthopedics Meeting. Brussels, Belgium, 3-4 June 1999.
34. Bell M, Fallaha M, Lenczner E, Ranger P, Welsh P: Viscosupplementation with hylan GF-20 in total knee replacement candidates: an effective pain management therapy that may delay surgery [poster]. Presented at: The Osteoarthritis Research Society International Meeting. Vienna, Austria, 16-19 September 1999.
35. Waddell D, Rein A, Panarites C, Coleman PM, Weiss C: Cost implications of introducing an alternative treatment for patients with osteoarthritis of the knee in a managed care setting. Am. J. Manag. Care 7(10), 981-991 (2001).
36. Kemper F, Gebhardt U, Meng T, Murray C: Tolerability and short-term effectiveness of hylan GF-20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr. Med. Res. Opin. 21(8), 1261-1269 (2005).
37. Stefanich RJ: Intra-articular corticosteroids in treatment of osteoarthritis. Orthop. Rev. 15, 65-71 (1986).
38. Pfenninger JL: Injections of joints and soft tissue, I: general guidelines. Am. Fam. Physician 44, 1196-1202 (1991).
39. Glaser DL, Schildorn JC, Bartolozzi AR et al.: Do you know what is on the tip of your needle? The inadvertent introduction of skin in to the joint. Arthritis Rheum. 43, S149 (2000).
40. Pal B, Morris J: Perceived risks of joint infection following intra-articular corticosteroid injections: a survey of rheumatologists. Clin. Rheumatol. 18, 264-265 (1999).
41. Gray RG, Tenenbaum J, Gotlieb NL: Local corticosteroid treatment in rheumatic disorders. Semin. Arthritis Rheum. 10, 231-254 (1981).
42. Hollander JL: Intrasynovial corticosteroid therapy in arthritis. Med. J. 19, 62 (1970).
43. Hamburger MI, Lakhanpal S, Mooar PA, Oster D: Intra-articular hyaluronans: a review of product-specific safety profiles. Semin. Arthritis Rheum. 32(5), 296-309 (2003).
44. Waddell DD: The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr. Med. Res. Opin. 19(7), 575-580 (2003).
45. Luzar MJ, Altawil B: Pseudogout following intraarticular injection of sodium hyaluronate. Arthritis Rheum. 41, 939-941 (1998).
46. Maillefert JF, Hirschhorn P, Pascaud F, Piroth C, Tavernier C: Acute attack of chondrocalcinosis after an intraarticular injection of hyaluronan. Rev. Rhum. Engl. Ed. 64, 593-594 (1997).
47. Goldberg VM, Coutts RD: Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin. Orthop. 419, 130-137 (2004).
48. Marino AA, Waddell DD, Kolomytkin OV, Pruett S, Sadasivan KK, Albright JA: Assessment of immunologic mechanisms for flare reactions to Synvisc. Clin. Orthop. Relat. Res. 442, 187-194 (2006).
49. Valiveti M, Reginato AJ, Falasca GF: Viscosupplementation for degenerative joint disease of shoulder and ankle. J. Clin. Rheumatol. 12(3), 162-163 (2006).
50. Coaccioli S, Pinoca F, Puxeddu A: Short term efficacy of intra-articular injection of hyaluronic acid in osteoarthritis of the first carpometacarpal joint in a preliminary open pilot study. Clin. Ter. 157(4), 321-325 (2006).
51. Brocq O, Tran G, Breuil V, Grisot C, Flory P, Euller-Ziegler L: Hip osteoarthritis: short term efficacy of viscosupplementation by hylan GF-20. An open-label study in 22 patients. Joint Bone Spine 69, 388-391 (2002).
52. Conrozier T, Bertin P, Mathieu P et al.: Intra-articular injections of hylan GF-20 in patients with symptomatic hip osteoarthritis: an open-label, multi-centre pilot study. Clin. Exp. Rheumatol. 21, 605-610 (2003).
53. Migliore A, Martin LS, Alimonti A, Valente C, Tormenta S: Efficacy and safety of viscosupplementation by ultrasound guided intra-articular injection in osteoarthritis of the hip. Osteoarthr. Cartil. 11, 305-306 (2003).
54. Conrozier T, Bertin P, Bailleul F et al.: Clinical response to intra-articular injections of hylan G-F 20 in symptomatic hip osteoarthritis: the OMERACT-OARSI criteria applied to the results of a pilot study. Joint Bone Spine 73(6), 705-709 (2006).